Whole Genome Sequencing for Surveillance of Antimicrobial Resistance in Actinobacillus pleuropneumoniae. by Bossé, Janine T et al.
Boss, JT; Li, Y; Rogers, J; Fernandez Crespo, R; Li, Y; Chaudhuri,
RR; Holden, MT; Maskell, DJ; Tucker, AW;Wren, BW; Rycroft, AN;
Langford, PR (2017) Whole Genome Sequencing for Surveillance of
Antimicrobial Resistance in Actinobacillus pleuropneumoniae. Front
Microbiol, 8. p. 311. ISSN 1664-302X DOI: 10.3389/fmicb.2017.00311
Downloaded from: http://researchonline.lshtm.ac.uk/3682739/
DOI: 10.3389/fmicb.2017.00311
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
fmicb-08-00311 March 2, 2017 Time: 16:34 # 1
ORIGINAL RESEARCH
published: 06 March 2017
doi: 10.3389/fmicb.2017.00311
Edited by:
Benoit Doublet,
National Institute for Agricultural
Research, France
Reviewed by:
Liang Li,
Los Angeles Biomedical Research
Institute, USA
Geovana Brenner Michael,
Friedrich-Loeffler-Institut, Germany
*Correspondence:
Janine T. Bossé
j.bosse@imperial.ac.uk
Paul R. Langford
p.langford@imperial.ac.uk
†Present address:
Roy R. Chaudhuri,
Department of Molecular Biology
and Biotechnology, University
of Sheffield, Firth Court, Western
Bank, Sheffield, UK;
Matthew T. G. Holden,
School of Medicine, University of
St Andrews, St Andrews, UK
‡These authors have contributed
equally to this work.
§ Members are listed in the
Acknowledgments section.
Specialty section:
This article was submitted to
Antimicrobials, Resistance
and Chemotherapy,
a section of the journal
Frontiers in Microbiology
Received: 15 November 2016
Accepted: 15 February 2017
Published: 06 March 2017
Citation:
Bossé JT, Li Y, Rogers J, Fernandez
Crespo R, Li Y, Chaudhuri RR,
Holden MTG, Maskell DJ,
Tucker AW, Wren BW, Rycroft AN,
and Langford PR
on behalf of the BRaDP1T Consortium
(2017) Whole Genome Sequencing
for Surveillance of Antimicrobial
Resistance in Actinobacillus
pleuropneumoniae.
Front. Microbiol. 8:311.
doi: 10.3389/fmicb.2017.00311
Whole Genome Sequencing for
Surveillance of Antimicrobial
Resistance in Actinobacillus
pleuropneumoniae
Janine T. Bossé1*‡, Yanwen Li1‡, Jon Rogers2, Roberto Fernandez Crespo1, Yinghui Li1,
Roy R. Chaudhuri3†, Matthew T. G. Holden4†, Duncan J. Maskell3, Alexander W. Tucker3,
Brendan W. Wren5, Andrew N. Rycroft6, and Paul R. Langford1* on behalf of the
BRaDP1T Consortium§
1 Section of Paediatrics, Department of Medicine, Imperial College London, London, UK, 2 Animal and Plant Health Agency,
Bury St Edmunds, UK, 3 Department of Veterinary Medicine, University of Cambridge, Cambridge, UK, 4 The Wellcome Trust
Sanger Institute, Cambridge, UK, 5 Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical
Medicine, London, UK, 6 Department of Pathology and Pathogen Biology, The Royal Veterinary College, Hatfield, UK
The aim of this study was to evaluate the correlation between antimicrobial resistance
(AMR) profiles of 96 clinical isolates of Actinobacillus pleuropneumoniae, an important
porcine respiratory pathogen, and the identification of AMR genes in whole genome
sequence (wgs) data. Susceptibility of the isolates to nine antimicrobial agents
(ampicillin, enrofloxacin, erythromycin, florfenicol, sulfisoxazole, tetracycline, tilmicosin,
trimethoprim, and tylosin) was determined by agar dilution susceptibility test. Except for
the macrolides tested, elevated MICs were highly correlated to the presence of AMR
genes identified in wgs data using ResFinder or BLASTn. Of the isolates tested, 57%
were resistant to tetracycline [MIC ≥ 4 mg/L; 94.8% with either tet(B) or tet(H)]; 48%
to sulfisoxazole (MIC ≥ 256 mg/L or DD = 6; 100% with sul2), 20% to ampicillin
(MIC ≥ 4 mg/L; 100% with blaROB−1), 17% to trimethoprim (MIC ≥ 32 mg/L; 100%
with dfrA14), and 6% to enrofloxacin (MIC ≥ 0.25 mg/L; 100% with GyrAS83F). Only
33% of the isolates did not have detectable AMR genes, and were sensitive by MICs
for the antimicrobial agents tested. Although 23 isolates had MIC ≥ 32 mg/L for tylosin,
all isolates had MIC ≤ 16 mg/L for both erythromycin and tilmicosin, and no macrolide
resistance genes or known point mutations were detected. Other than the GyrAS83F
mutation, the AMR genes detected were mapped to potential plasmids. In addition to
presence on plasmid(s), the tet(B) gene was also found chromosomally either as part of
a 56 kb integrative conjugative element (ICEApl1) in 21, or as part of a Tn7 insertion in
15 isolates. Our results indicate that, with the exception of macrolides, wgs data can be
used to accurately predict resistance of A. pleuropneumoniae to the tested antimicrobial
agents and provides added value for routine surveillance.
Keywords: animal infections, antimicrobial resistance genes, integrative conjugative elements, plasmids,
genomics, respiratory tract, Pasteurellaceae
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INTRODUCTION
Antimicrobial resistance (AMR) in bacteria from food-producing
animals is a growing concern (Michael et al., 2015). Extensive use
of antimicrobial agents for treatment and prevention of diseases
fosters an environment in which resistance determinants are
acquired and maintained by pathogens, as well as commensal
bacteria. In the UK, the swine industry accounts for a
large proportion of the antimicrobial agents sold for use in
food-producing animals; with tetracyclines, beta-lactams, and
trimethoprim/sulphonamides being the most commonly used
antimicrobial agents (Burch, 2005; Borriello, 2013).
Actinobacillus pleuropneumoniae is a major contributor to
swine respiratory disease, causing considerable economic losses
worldwide. Strategies to reduce the incidence and severity of
disease include good husbandry, vaccination, and antibiotic
treatment. The latter is essential to limit the severity and
spread of pleuropneumonia. Knowledge of resistance profiles for
A. pleuropneumoniae is required to inform treatment decisions.
Furthermore, this information contributes to the larger picture
of AMR in bacteria of animal origin (Hendriksen et al., 2008; El
Garch et al., 2016).
Typically, determination of antimicrobial susceptibility
is done either by disk diffusion or minimum inhibitory
concentration (MIC) assays. Identification of the genetic
determinants of resistance not only corroborates phenotypic
results, but is also useful for epidemiological purposes, as there
are often multiple different genes that can confer resistance
to a given antimicrobial agent. Both PCR and microarray
hybridization have been used to detect the presence of genes
encoding resistance phenotypes, but these assays are limited to
detecting the sequences tested, and do not allow direct detection
of mutations conferring resistances (Frye et al., 2010; Ledeboer
and Hodinka, 2011). It has recently been proposed that whole
genome sequencing (wgs) may be an alternative for routine
surveillance of resistance profiles and for identification of
emerging resistances (Zankari et al., 2013). We recently used wgs
to identify (for the first time) dfrA14 as the genetic determinant
of trimethoprim resistance detected in 16 clinical isolates of
A. pleuropneumoniae (Bossé et al., 2015b). In this study, we
compare the MIC profiles for nine antimicrobial agents with
detection of resistance genes in wgs data of 96 isolates.
MATERIALS AND METHODS
Bacterial Strains and Antimicrobial
Susceptibility Testing
A total of 96 clinical A. pleuropneumoniae isolates from the
UK, previously tested for trimethoprim resistance (Bossé et al.,
2015b), were analyzed using the agar dilution susceptibility
assay, according to the CLSI VET01-A4 guidance (Clinical and
Laboratory Standards Institute [CLSI], 2013), for determination
of MICs for tetracycline, ampicillin, sulfisoxazole, enrofloxacin,
erythromycin, tilmicosin, tylosin, and florfenicol. Some
samples were re-tested for resistance using the disk diffusion
susceptibility test according to the CLSI VET01-A4 guidance
(Clinical and Laboratory Standards Institute [CLSI], 2013).
A. pleuropneumoniae ATCC 27090 and Histophilus somni ATCC
70025 were used as controls for all susceptibility tests. All clinical
A. pleuropneumoniae isolates had been cultured from pneumonic
lungs of pigs submitted for post-mortem to the then Animal
Health and Veterinary Laboratory Agency (now Animal and
Plant Health Agency) diagnostic laboratories in England (see
Supplementary Table S1 for details). The serovar of each isolate
was determined by PCR as previously described (Bossé et al.,
2014).
Genome Sequencing and Analysis
Genomic DNA was prepared from all isolates using the FastDNA
Spin kit (MP Biomedicals), and 0.5 µg were used for library
preparation and paired-end sequencing (Illumina HiSeq 2000),
as previously described (Howell et al., 2013; Bossé et al., 2015b;
Weinert et al., 2015). Cutadapt (Martin, 2011) was used to
remove Illumina adapter sequences, and Sickle1 was used to
trim low-quality sequences from the ends of reads, prior to
assembly into contigs using Velvet 1.2.08 (Zerbino and Birney,
2008) and VelvetOptimiser 2.2.5 (Gladman and Seemann, 2012).
Assemblies with N50 < 10000 were excluded from further
analysis. The draft genome sequence for each isolate in this study
has been deposited in the European Nucleotide Archive2, and
accession numbers are listed in Supplementary Table S1.
AMR genes were identified in the draft genomes using
ResFinder (Zankari et al., 2012), with a threshold of 98% identity
and minimum length of 60%. Alternatively, the genomes were
queried by BLASTn and tBLASTn using sequences of known
resistance genes from A. pleuropneumoniae and other members
of the Pasteurellaceae found in GenBank (Supplementary Table
S2). Clustal alignments were used to compare the gyrA, gyrB,
parC, and parE genes in isolates with elevated MICs for
enrofloxacin (≥0.25 mg/L) with those genes in all remaining
isolates in order to identify any mutations that could contribute
to enrofloxacin resistance. The profiles of resistance genes
identified were then compared to the results of the MIC assays,
and where discrepancies were found, isolates were re-tested for
susceptibility by disk diffusion, and by PCR for the presence of the
specific AMR genes using primers listed in Table 1. Correlations
between resistance phenotypes and genotypes were calculated
using Fisher’s exact test function (‘fisher.test’) in R (version 3.3.2).
RESULTS
Full results of the testing and identification of AMR genes for
each isolate are also shown in Supplementary Table S1. The
correlations between presence of identified AMR genes and
resistance phenotype are shown in Table 2. The majority of the
96 isolates tested in this study, representing serovars 2 (11.5%),
6 (7.3%), 7 (10.4%), 8 (68.8%), and 12 (2.1%), were collected
between 2005 and 2009, with smaller numbers representing the
other years between 1998 and 2011 (Supplementary Table S1).
1https://github.com/najoshi/sickle
2http://www.ebi.ac.uk/ena
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TABLE 1 | Primers used in this study.
Primer name Sequence Amplicon size Source
sul2_for TCAACATAACCTCGGACAGTTTCTC 212 bp Bossé et al., 2015a
sul2_rev GGGAATGCCATCTGCCTTGAGC
dfrA14_for CATTGATAGCTGCGAAAGCGAAAAACGGC 343 bp Bossé et al., 2015b
dfrA14_rev ATCGTCGATAAGTGGAGCGTAGAGGC
blaRob_for GCTGACATTAACGGCTTGTTCGC 820 bp This study
blaRob_rev TTTGGCTTCTTCGGTAAATTGCG
tetB_for TTTGCGCTGTAGTGCTCCAAT 944 bp This study
tetB_rev AACAAATAAAGTTGCTCGAAAGTA
tetH_for TAAATACGGCAGAAAACCCATCTTGC 106 bp This study
tetH_rev GCGCCCAATATAGAGCATCCAAAGTG
TABLE 2 | Correlation of phenotypic resistance to selected antimicrobial agents and presence of specific resistance genes detected in draft genomes of
96 Actinobacillus pleuropneumoniae isolates from the UK.
Antimicrobial
agenta
Number of isolates
resistant by genotypeb
Number of isolates resistant
by phenotype (associated MIC)
Correlation of genotype
with phenotypec
Tetracycline 55 58 (MIC ≥ 4 mg/L) 94.8% (p < 2.2e-16)
Ampicillin 19 19 (MIC ≥ 4 mg/L) 100% (p < 2.2e-16)
Sulfisoxazole 46 46 (MIC ≥ 256 mg/L, or DD = 6 mm)d 100% (p < 2.2e-16)
Trimethoprim 16 16 (MIC ≥ 32 mg/L) 100% (p < 2.3e-16)
Enrofloxacin 6 6 (MIC ≥ 0.25 mg/L) 100% (p < 1.1e-09)
aNo isolates were resistant to florefenicol, and no florfenicol resistance genes were detected in the genomes. No specific macrolide resistance genes were identified,
and phenotypic resistance to erythromycin, tilmicosin and tylosin was not clear from the MIC values obtained (see Supplementary Table S1 for further details). bSpecific
genes detected for each resistance phenotype: tet(B) or tet(H) for tetracycline, blaROB-1 for ampicillin, sul2 for sulfisoxazole; dfrA14 for trimethoprim, and GyrAS83F for
enrofloxacin resistant isolates. cCorrelation between resistant phenotype and genotype was calculated using Fisher’s exact test function (‘fisher.test’) in R (version 3.3.2).
d Initially, two isolates with sul2 identified in their genomes had an MIC ≤ 16 mg/L, however re-test by disk diffusion showed a zone of inhibition of 6 mm, indicative of
resistance. Poor solubility of sulfisoxazole may have caused the discrepancy.
Only 33% of the isolates did not have any AMR genes, whereas
20% carried a single, and 47% two or more AMR genes. None of
the isolates tested were resistant to florefenicol, and no florfenicol
resistance genes were detected in the genomes.
The MICs for ampicillin showed clear separation into low
MIC (MIC ≤ 2 mg/L) for isolates with no resistance gene
detected, and high MIC (MIC ≥ 8 mg/L) for 18 isolates with
blaROB−1 detected by ResFinder. One isolate (MIDG3354) with
an MIC = 4 mg/L also had blaROB−1 detected by ResFinder.
Thus, there was 100% correlation between the presence of
blaROB−1 and an MIC ≥ 4 mg/L for ampicillin. In all cases,
the blaROB−1 gene identified showed 99.9% identity with that
found in the plasmid pB1000 (accession number DQ840517)
from Haemophilus parasuis (San Millan et al., 2007). For all but
one isolate, the full 918 bp blaROB−1 sequence was identified
on a single contig. In MIDG3443, where only 857/918 bp
were identified by ResFinder, BLASTn confirmed that the entire
blaROB−1 sequence was present, but split over two contigs.
For tetracycline, 94.8% of isolates considered phenotypically
resistant (MIC ≥ 4 mg/L) were found to carry either tet(B)
or tet(H). A 100% correlation was found between the presence
either of these genes and an MIC ≥ 8 mg/L. We found of four
isolates with an MIC = 4 mg/L, only one (MIDG2567) carried a
resistance gene, tet(B), whereas three other isolates (MIDG3342,
MIDG3352, and MIDG3356) had no detectable tetracycline
resistance gene. The tet(B) gene identified by ResFinder showed
99.9% to 100% identity with a 1206 bp gene found in the
Shigella flexneri 2a SRL pathogenicity island (accession number
AF326777) or the S. flexneri 2b plasmid R100 (accession number
AP000342). In some cases, the gene was split over two contigs
(with only one part identified by ResFinder), as confirmed by
BLASTn. In five isolates, tet(H) genes were identified that had
either 99.9% identity with the 1179 bp gene found in Pasteurella
aerogenes plasmid pPAT1 (accession number AJ245947) or 100%
identity with the 1203 bp sequence found in Pasteurella multocida
plasmid pPMT1 (accession number Y15510). These two genes
differ at their 3′ ends, and BLASTn analysis confirmed the
presence of the 1203 bp gene in four A. pleuropneumoniae
isolates, and the 1179 bp sequence in one.
For trimethoprim, there was a 100% correlation between an
MIC ≥ 32 mg/L and the presence of dfrA14 in 16 isolates,
as previously described (Bossé et al., 2015b). Isolates lacking
dfrA14 had an MIC ≤ 4 mg/L, showing clear separation from
the trimethoprim-resistant isolates. There was also a 100%
correlation between an MIC≥ 256 mg/L for sulfisoxazole and the
presence of the sul2 gene in 44 isolates (MIC ≥ 512 mg/L for 39
of these). In two isolates, MIDG2652 and MID3362, initial results
(MIC ≤ 16 mg/L) indicated susceptibility despite the presence
of the sul2 gene. PCR confirmed the presence of sul2 in these
isolates, and resistance to sulfisoxazole was confirmed by disk
diffusion (zone of inhibition= 6 mm). The sul2 gene identified by
ResFinder shared 100% with an 816 bp gene from Acinetobacter
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bereziniae (accession number GQ421466). In cases where less
than 816 bp of the gene were identified by ResFinder, BLASTn
confirmed the presence of the remaining sequence on a separate
contig.
The six isolates with elevated MICs for enrofloxacin
(≥0.25 mg/L) all had identical sequences for their gyrA, gyrB,
parA, and parE genes. The amino acid sequence for each
conserved protein encoded by these genes was used to search
(by tBLASTn) the remaining genomes in order to determine
if any mutations could account for the increased resistance
to enrofloxacin. Compared to the sequences found in the
enrofloxacin-sensitive isolates, no mutations were found in GyrB,
ParA or ParC, however, a substitution in the GyrA sequence
(S83F) was found only in the six isolates with MICs for
enrofloxacin ≥ 0.25 mg/L.
All isolates had an MIC ≤ 16 mg/L for both erythromycin
and tilmicosin, whereas there was a clear separation into low
(MIC ≤ 2 mg/L) and high (MIC ≥ 32) levels of resistance to
tylosin. However, no macrolide resistance genes were identified
by ResFinder in any of the isolates, nor were any mutations
detected in the 23S rRNA gene, or in the genes encoding
ribosomal proteins L4 and L22 (rplD and rplV, respectively).
DISCUSSION
Recently, several groups have investigated the use of genome
sequencing as an alternative/adjunct to phenotypic testing for
detection and surveillance of AMR in different bacteria (Zankari
et al., 2013; Gordon et al., 2014; Köser et al., 2014; Walker et al.,
2015; Zhao et al., 2016). For each bacterium, it is necessary
to determine the correlation between genetic detection of a
resistance gene with phenotypic determination of resistance in
order to validate the usefulness of a wgs approach.
In this study, we investigated 96 clinical isolates of
A. pleuropneumoniae, an important respiratory pathogen of
pigs, and found a high correlation between the presence of
specific AMR genes and elevated MICs for the corresponding
antimicrobial agents tested. However, the results of macrolide
testing are inconclusive. Although 20 isolates had an
MIC ≥ 32 mg/L for tylosin (seven of which had an
MIC ≥ 64 mg/L), all isolates had an MIC ≤ 16 mg/L for
both erythromycin and tilmicosin, and no macrolide resistance
genes were detected by ResFinder. Furthermore, no point
mutations known to confer resistance to macrolides (e.g., in
rplV, rplD, rumA, or the 23S rRNA genes) were detected by
BLASTn in any of the isolates with elevated MICs for tylosin.
In other studies, where specific macrolide resistance genes
were identified in members of the Pasteurellaceae (Olsen et al.,
2015; Dayao et al., 2016), higher MIC values (≥64 mg/L)
were reported for tilmicosin and erythromycin. There is no
established CLSI clinical MIC breakpoint for tylosin resistance
in A. pleuropneumoniae, and a recent VetPath survey (El
Garch et al., 2016) also showed that although only 1/158 A.
pleuropneumoniae isolates tested had an MIC ≥ 32 mg/L for
tilmicosin (considered resistant), 144/158 had an MIC≥ 32 mg/L
for tylosin (none considered resistant due to lack of established
breakpoint). From these and our results, it is not clear if there is a
specific resistance to tylosin associated with an MIC ≥ 64 mg/L,
and if so, what is the mechanism of this resistance.
All six isolates with an MIC ≥ 0.25 mg/L for enrofloxacin
had an identical amino acid exchange (S83F) in the GyrA
protein, which is in agreement with a previous study in A.
pleuropneumoniae (Wang et al., 2010). Wang et al. (2010) also
reported that combinations of this and other mutations in gyrA,
parC, and parE were associated with higher levels of resistance
to enrofloxacin (MIC ≥ 1 mg/L), but these were not detected
in our isolates. The six isolates with reduced susceptibility to
enrofloxacin were isolated from samples submitted to the same
APHA laboratory (Langford), and five were in the same year.
Enrofloxacin resistance does not appear to be widespread in
A. pleuropneumoniae isolates in the UK.
For trimethoprim resistance, there was a 100% correlation
between the presence of dfrA14 and an MIC ≥ 32 mg/L, as
previously reported (Bossé et al., 2015b). Although only 16
of the tested isolates were resistant to trimethoprim, all of
these also carried the sul2 gene and had an MIC ≥ 512 mg/L
for sulfisoxazole. The sul2 gene was detected in a total of
46 isolates, however, phenotypic detection of resistance to
sulfisoxazole was problematic in some of these. Although 85%
of the isolates carrying sul2 had an MIC ≥ 512 mg/L, and
96% an MIC ≥ 256 mg/L, two isolates initially showed an
MIC ≤ 16 mg/L. When re-tested by disk diffusion, these two
isolates showed a zone of 6 mm, consistent with a resistant
phenotype (Clinical and Laboratory Standards Institute [CLSI],
2013). Issues with the solubility of sulfisoxazole may account for
the discrepancies. Co-location of the dfrA14 and sul2 genes in
two distinct plasmids (Bossé et al., 2015b) accounts for the 16
isolates with resistance to both trimethoprim and sulfisoxazole.
Analysis of the sequences flanking sul2 in the isolates lacking
dfrA14 indicate other possible plasmids that will require further
investigation. Only two of the isolates carrying sul2 had no
other detectable AMR genes. The remaining 44 all had tet(B)
or tet(H), with eighteen also carrying blaROB−1, and eight of
these with dfrA14 as well. A further eight isolates carried a
combination of tet(B), sul2 and dfrA14, but lacked the blaROB−1
gene (Supplementary Table S1).
There was a 100% correlation between the presence of
blaROB−1 in 19 isolates and an MIC≥ 4 mg/L for ampicillin; with
an MIC≥ 8 mg/L in 18 of these. The sequences flanking blaROB−1
indicate possible plasmids. Further investigation is required in
order to determine if these represent known plasmid(s) described
in other Pasteurellaceae, such as pB1000 (San Millan et al., 2007)
or pJMA-1 (Moleres et al., 2015) or unique plasmids not yet
described.
In 98% of isolates carrying either tet(B) or tet(H), an
MIC ≥ 8 mg/L for tetracycline was detected. One isolate
with an MIC = 4 mg/L contained the tet(B) gene, whereas
a further three isolates with an MIC = 4 mg/L did not have
any tetracycline resistance genes detected. The reason for this
discrepancy is not clear. The sequences flanking tet(H) indicate
possible plasmid(s), whereas tet(B) was found either on small
contigs with sequences related to possible plasmid(s), or on
larger contigs with sequences indicating a chromosomal insertion
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site. In 21 isolates with the latter, we recently identified a
56 kb integrative conjugative element (ICE), ICEApl1, inserted
in a tRNA-Leu (TAA) gene, which contains tet(B) as part of
a Tn10 insertion (Bossé et al., 2016). In 15 other isolates with
tet(B) on large contigs, the sequence appears to part of a Tn7
insertion disrupting the competence related gene, comM (see
Supplementary Table S1). The majority (55/96) of isolates tested
were resistant to tetracycline, and only 11 of these carried no
other detectable AMR gene.
Reproducibility of phenotypic results has been an issue with
surveillance of AMR, with calls for a more standardized method
to allow direct comparisons between labs (Michael et al., 2015;
El Garch et al., 2016). Our results confirm that wgs is a
valuable method that can be used, either in combination with
phenotypic testing or on its own, for surveillance of AMR in
A. pleuropneumoniae. In each isolate where an AMR gene was
identified, phenotypic results confirmed resistance. In the case
of macrolides, no genes were identified and it is not clear what
MIC for tylosin should be considered as a breakpoint indicating
resistance. Genome sequencing not only identifies specific AMR
genes, but also gives an indication of their locations, either
within the chromosome or on plasmids. ResFinder was useful for
identifying and locating known AMR gene sequences within the
draft genomes, though in cases where a sequence was split over
multiple contigs, only the contig with the larger proportion of
the gene was identified. ResFinder is also not capable of detecting
point mutations in genes such as gyrA that lead to a resistance
phenotype. In these cases, BLASTn or tBLASTn can be used to
either detect mutations or to determine the location of missing
sequences not identified by ResFinder.
Plasmids are the biggest contributors to the spread of AMR,
with dissemination occurring not only through clonal expansion
of the isolates harboring them, but also by conjugal transfer
when genes expressing the required machinery are present.
Tracking the spread of AMR genes/plasmids provides important
epidemiological information that can best be provided by wgs
data. Plasmid sequences are often distributed over multiple small
contigs within draft genomes, suggesting either repeat sequences
within the plasmid, or the presence of multiple plasmids sharing
common backbone sequences. Plasmid isolation and sequencing
can determine if a single or multiple small plasmids are present,
as has been described for P. multocida (San Millan et al., 2009),
especially in the case of isolates resistant to multiple antimicrobial
agents. Most small plasmids that have been characterized in
A. pleuropneumoniae and other Pasteurellaceae are mobilisable,
but do not harbor genes encoding conjugal transfer machinery
(Blanco et al., 2007; Matter et al., 2008; Kang et al., 2009;
San Millan et al., 2009; Bossé et al., 2015a,b). These plasmids
can be disseminated either via clonal expansion or conjugation.
The latter mechanism requires the presence of other replicons
encoding the required machinery, such as the recently described
ICE (ICEApl1, ICEMh1, ICEPmu1), discovered in the genomes
of different Pasteurellaceae species (Michael et al., 2012; Eidam
et al., 2015; Bossé et al., 2016). As more wgs become available for
members of the Pasteurellaceae, it is likely that more ICE will be
identified, and their role in dissemination of small plasmids can
be further investigated.
In summary, genome sequencing is likely to be used
increasingly in the surveillance of AMR, providing a standard
method that can be easily compared between different
laboratories in different countries. This method can be used
on its own for identification of known resistance genes, or in
conjunction with sensitivity testing where resistance mechanisms
have yet to be identified. Furthermore, wgs data can provide
more information than just AMR genotypes, it can also give
insights into the mechanisms allowing spread of resistance
amongst isolates.
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